Blocking Dkk‑1 to fight osteosarcoma using insights from pet dogs
A Dkk-1 targeting antisense therapy for human osteosarcoma, developed with help from man’s best friend
['FUNDING_R21'] · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · NIH-11251622
A gene‑targeting antisense drug that blocks the protein Dkk‑1 is being developed to help people (including children) with osteosarcoma.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR (nih funded) |
| Locations | 1 site (COLLEGE STATION, UNITED STATES) |
| Trial ID | NIH-11251622 on ClinicalTrials.gov |
What this research studies
Researchers are developing an antisense molecule that stops tumors from making Dkk‑1, a protein linked to bone damage and cancer spread. In mice, a Dkk‑1 blocker reduced bone destruction, slowed tumor growth, and lowered lung metastases, and a dog‑specific version (cDkkMo) has been made. Because canine osteosarcoma closely resembles the human disease, the team plans veterinary trials in pet dogs at Texas A&M to study safety and effectiveness. Cell culture, mouse models, and client‑owned dogs will be used to gather data that could support future human trials.
Who could benefit from this research
Good fit: People diagnosed with osteosarcoma—especially pediatric cases or those whose tumors produce Dkk‑1—would be the intended beneficiaries and candidates for future trials.
Not a fit: Patients whose tumors do not rely on Dkk‑1 or who have other cancer types are unlikely to benefit from this specific therapy.
Why it matters
Potential benefit: If successful, this approach could reduce bone damage, slow tumor growth, and lower metastatic spread in osteosarcoma, improving survival and quality of life.
How similar studies have performed: Preclinical mouse studies showed promising tumor and bone‑protective effects of Dkk‑1 blockade, but translating this to dogs and humans is a novel step.
Where this research is happening
COLLEGE STATION, UNITED STATES
- TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR — COLLEGE STATION, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GREGORY, CARL A. — TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
- Study coordinator: GREGORY, CARL A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.